304 North Cardinal St.
Dorchester Center, MA 02124
Product name: Rutinib Cream
Manufcturer: Drug International
Per tube contain: INN 1.5
Rutinib-cream-Ruxolitinib is a Prescription medication that inhibits Janus kinase (JAK) and is recommended for short-term topical treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients aged 12 years and above. This treatment is suitable for those whose condition is not adequately managed with prescribed topical therapies, or when such therapies are not recommended. It is produced by Drug International Ltd. in Bangladesh. 
Rutinib Cream with Ruxolitinib is an innovative skincare formula that combines the rejuvenating properties of Rutinib with the proven effectiveness of Ruxolitinib. This unique blend can help improve the firmness, smoothness, and overall appearance of your skin. With Rutinib Cream, you can unlock the true potential of your skin and achieve a radiant, youthful look. Try it today and see the remarkable difference it can make in your skincare routine. 
Composition: Ruxolitinib Phosphate INN 1.5% cream. Also known as Rutinib Cream INN 1.5.
Rutinib cream is a prescription medicine used on the skin (topical) to treat:
Rutinib cream works by blocking the activity of Janus kinases (JAKs), which are proteins that play a role in inflammation. By blocking JAKs, Rutinib cream can help reduce inflammation and improve the appearance of the skin.
Apply Rutinib cream to the affected areas of the skin twice a day (BID).
. It is important to follow the instructions of your doctor carefully. Rutinib cream is not for use on the face, lips, or eyelids.
Rutinib cream is an effective topical Janus kinase (JAK) inhibitor. JAKs are enzymes that aid in the process of signal transduction, which involves communication between cells. These enzymes have a significant impact on various cellular processes, including inflammation, cell growth, and differentiation.
Rutinib cream works by specifically targeting JAK1 and JAK2, which helps to reduce inflammation and improve the skin’s appearance. In the case of atopic dermatitis, Rutinib cream works by decreasing the levels of pro-inflammatory cytokines such as IL-4, IL-13, and IL-31 that contribute to inflammation.
In vitiligo, Rutinib cream works by reducing the activity of T-cells, a type of white blood cell that contributes to inflammation. T-cells destroy Melanocytes, which are responsible for producing melanin, which gives skin its color. By reducing inflammation and T-cell activity, Rutinb cream can improve the appearance of the skin in both atopic dermatitis and vitiligo.
While Rutinib cream is a new treatment for these conditions, it has shown promising results in clinical trials. However, Long-term safety and effectiveness of Ruxoilitinib are still being investigated. 
Apply a thin layer of Rutinib cream twice daily (BID) to the affected areas of the skin. Do not apply Ruxoilitinib cream to the face, lips, or eyelids.
Do not treat more than 20% of the body surface area (BSA) with Ruxoilitinib at one time. The maximum weekly dose of Rutinib cream is 60 grams.
The skin absorbs Rutinib cream and delivers it into the bloodstream. The amount of Ruxoilitinib absorbed depends on the amount of cream applied, the area of skin treated, and the thickness of the skin. 
In clinical studies, the average peak plasma concentration of Ruxoilitinib was 449 nM in adults and 110 nM in adolescents after applying ruxolitinib to 20% of the BSA twice daily. The systemic exposure to Ruxoilitinib after topical application is significantly lower than the systemic exposure to ruxolitinib after oral administration.
Rutinib cream is generally safe and well-tolerated. The most common side effects are mild and go away on their own. However, Ruxoilitinib cream can cause serious side effects, such as infections and blood clots.
It is important to talk to your doctor about the risks and benefits of Ruxoilitinibruxolitinib before using it.
Ruxolitinib cream has mild side effects such as nasal congestion, bronchitis, ear infections, increased eosinophil count, hives, diarrhea, folliculitis, tonsillitis, and a runny nose. Less common side effects include application site dermatitis, hypertension, anxiety, contact dermatitis, diarrhea, ear infections, gastritis, gastroenteritis, hordeolum, influenza-like illness, insomnia, nasal congestion, and vomiting. Serious side effects include weakening the immune system, increasing the risk of infections, and increasing the risk of blood clots in the legs or lungs, which can be life-threatening.  
Opzelura, a topical Janus kinase (JAK) inhibitor, treats nonsegmental vitiligo in adults and children aged 12 and older, which is caused by an autoimmune attack on melanocytes that produce melanin. Ruxolitinib reduces inflammation and T-cell activity, which contributes to the destruction of melanocytes in vitiligo. Clinical trials have shown that ruxolitinib improves repigmentation in vitiligo patients, with 52% of patients achieving a 75% improvement in their Facial Vitiligo Area Scoring Index (F-VASI75) after 52 weeks. While most common side effects are mild, serious side effects like infections and blood clots can occur. It is crucial to consult a doctor about the risks and benefits of ruxolitinib. 
To order Rutinib cream online Contact with us–
Whats app and Wechat: +8801304498958
for more information contact us.
To order other oncology product visit our product page.